Frequent URINATION at night that interrupts sleep. It is often associated with outflow obstruction, DIABETES MELLITUS, or bladder inflammation (CYSTITIS).
Abnormalities in the process of URINE voiding, including bladder control, frequency of URINATION, as well as the volume and composition of URINE.
Agents that reduce the excretion of URINE, most notably the octapeptide VASOPRESSINS.
Urination of a large volume of urine with an increase in urinary frequency, commonly seen in diabetes (DIABETES MELLITUS; DIABETES INSIPIDUS).
Symptom of overactive detrusor muscle of the URINARY BLADDER that contracts with abnormally high frequency and urgency. Overactive bladder is characterized by the frequent feeling of needing to urinate during the day, during the night, or both. URINARY INCONTINENCE may or may not be present.
Symptoms of disorders of the lower urinary tract including frequency, NOCTURIA; urgency, incomplete voiding, and URINARY INCONTINENCE. They are often associated with OVERACTIVE BLADDER; URINARY INCOMPETENCE; and INTERSTITIAL CYSTITIS. Lower urinary tract symptoms in males were traditionally called PROSTATISM.
Involuntary discharge of URINE during sleep at night after expected age of completed development of urinary control.
A sympathomimetic that acts mainly by causing release of NOREPINEPHRINE but also has direct agonist activity at some adrenergic receptors. It is most commonly used as a nasal vasoconstrictor and an appetite depressant.
A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.
A plant species of the family Apiaceae that contains COUMARINS.
Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
The mechanical laws of fluid dynamics as they apply to urine transport.
## I'm sorry for any confusion, but "Alabama" is not a medical term or concept. It is a geographical location, referring to the 22nd state admitted to the United States of America, located in the southeastern region. If you have any questions related to healthcare, medicine, or health conditions, I'd be happy to help with those!
Phenylpropionates are a class of organic compounds, including certain drugs such as ephedrine and pseudoephedrine, which contain a phenylethanoic acid structure with a propionate substitution.
Cresols, also known as hydroxytoluene, are a group of phenolic compounds including ortho-cresol, meta-cresol, and para-cresol, which differ in the position of the hydroxyl group on the benzene ring.

Polynocturia in chronic kidney disease is related to natriuresis rather than to water diuresis. (1/56)

BACKGROUND: Nocturnal polyuria has been well known in renal insufficiency. Recently, we found that as renal function deteriorated in chronic kidney disease (CKD), natriuresis was enhanced during the night with nocturnal blood pressure elevation. In the present study, we investigated whether nocturnal polyuria in CKD was due to the inability to concentrate urine, as previously proposed, or based on osmotic diuresis mainly by natriuresis. METHODS: In 27 CKD patients, circadian rhythms of urinary sodium, potassium, urea and osmolar excretion rates (U(Na)V, U(K)V, U(urea)V, U(osm)V) as well as of urinary volume (V) and free-water clearance (C(H(2)O)) were estimated during both daytime (6:00 to 21:00) and nighttime (21:00 to 6:00). Then, the night/day ratios of these parameters were analysed in relation to creatinine clearance (C(cr)) as a marker of glomerular filtration rate. RESULTS: C(cr) had significantly negative relationships with night/day ratios of V (R = -0.69; P < 0.0001), U(osm)V (R = -0.54; P = 0.004) and U(Na)V (R = -0.63; P = 0.0005), but no correlation with night/day ratios of C(H(2)O) (R = -0.33; P = 0.1), U(K)V (R = -0.29; P = 0.1) or U(urea)V (R = -0.31; P = 0.1). Linear and multiple regression analysis identified nocturnal natriuresis rather than urea excretion as an independent determinant of nocturia. CONCLUSION: As renal function deteriorated, nocturnal polyuria was seen, being consistent with classical recognition. Furthermore, this increase in nocturnal urine volume seemed related to osmotic diuresis mainly by natriuresis rather than to water diuresis or urea excretion.  (+info)

Assessing urgency in interstitial cystitis/painful bladder syndrome. (2/56)

OBJECTIVES: Interstitial cystitis/painful bladder syndrome (IC/PBS) at present is a symptom-based diagnosis. The Interstitial Cystitis Symptom Index (ICSI), also known as the O'Leary-Sant Symptom Index, is a widely used scale that assesses the four cardinal symptoms of IC/PBS (ie, bladder pain, urgency, frequency, and nocturia), by asking how often each is experienced. In an ongoing case-control study of recent-onset IC/PBS, we compared the ICSI with a series of questions that addressed the severity of these symptoms. METHODS: Recruiting nationally, we enrolled women with IC/PBS symptoms of 12 months' duration or less. We assessed the severity of pain, frequency, and urgency using Likert and categorical scales, and how often these symptoms were experienced using the ICSI. We compared these scales by frequency distributions and interscale correlations. RESULTS: In 138 women with recent-onset IC/PBS, the scores for frequency were correlated and, for pain, appeared to be complementary. However, for urgency, the ICSI question of "the strong need to urinate with little or no warning" consistently yielded lower scores than the severity question of "the compelling urge to urinate that is difficult to postpone." Some patients denied urgency to the ICSI question yet reported intense urgency to the severity question. CONCLUSIONS: Compared with the severity question, the ICSI underestimated the prevalence and degree of urgency. This observation is consistent with the views of others that sudden urgency does not define the sensation experienced by many patients with IC/PBS. Clarifying this symptom description may assist in developing a usable case definition for IC/PBS.  (+info)

Papillary cystadenocarcinoma of the prostate: a case report. (3/56)

A 91-year-old man presented with nocturnal frequency and urge incontinence of a few days duration due to involvement of prostate cancer (PCa) accompanied by a large cyst in the left lobe of the prostate gland and urinary bladder wall. Channeling transurethral resection of prostate was performed to relieve the main symptoms and the resected material was histologically diagnosed as papillary cystadenocarcinoma arising from the epithelium of microscopic retention cysts. Following shrinkage of the large cyst, the patient is doing well on a combination regimen of a luteinizing hormone-releasing hormone analogue and bicaltamide. Papillary cystadenocarcinoma of the prostate was originally defined as papillary PCa arising from, not accompanied by, prostatic cysts. Cysts associated with PCa are subdivided into primary (or true) and secondary (or pseudo) cysts. Cancer cells in primary cysts originate from the epithelial lining. Papillary growth type cysts belong to this group and are regarded as papillary cystadenocarcinoma. The secondary (or pseudo) cysts, which have no epithelial lining and consist of hemorrhagic and/or necrotic contents are associated with invasive PCa. In the present case, the microscopic retention cysts revealed by histologic examination were of the primary type. This case of papillary cystadenocarcinoma, arising from a primary cyst, is the 13th such report from among previously reported cases in Japan.  (+info)

Is the prevalence of overactive bladder overestimated? A population-based study in Finland. (4/56)

BACKGROUND: In earlier studies, one in six adults had overactive bladder which may impair quality of life. However, earlier studies have either not been population-based or have suffered from methodological limitations. Our aim was to assess the prevalence of overactive bladder symptoms, based on a representative study population and using consistent definitions and exclusions. METHODOLOGY/PRINCIPAL FINDINGS: The aim of the study was to assess the age-standardized prevalence of overactive bladder defined as urinary urgency, with or without urgency incontinence, usually with urinary frequency and nocturia in the absence of urinary tract infection or other obvious pathology. In 2003-2004, a questionnaire was mailed to 6,000 randomly selected Finns aged 18-79 years who were identified from the Finnish Population Register Centre. Information on voiding symptoms was collected using the validated Danish Prostatic Symptom Score, with additional frequency and nocturia questions. Corrected prevalence was calculated with adjustment for selection bias due to non-response. The questionnaire also elicited co-morbidity and socio-demographic information. Of the 6,000 subjects, 62.4% participated. The prevalence of overactive bladder was 6.5% (95% CI, 5.5% to 7.6%) for men and 9.3% (CI, 7.9% to 10.6%) for women. Exclusion of men with benign prostatic hyperplasia reduced prevalence among men by approximately one percentage point (to 5.6% [CI, 4.5% to 6.6%]). Among subjects with overactive bladder, urgency incontinence, frequency, and nocturia were reported by 11%, 23%, and 56% of men and 27%, 38%, and 40% of women, respectively. However, only 31% of men and 35% of women with frequency, and 31% of subjects of both sexes with nocturia reported overactive bladder. CONCLUSIONS/SIGNIFICANCE: Our results indicate a prevalence of overactive bladder as low as 8% suggesting that, in previous studies, occurrence has been overestimated due to vague criteria and selected study populations regarding age distribution and low participation.  (+info)

Clinical manifestations associated with HTLV type I infection: a cross-sectional study. (5/56)

Human T-lymphotropic virus type I (HTLV-I) causes HTLV-I-associated myelopathy/tropical spastic paraparesis and adult T cell leukemia in a small percentage of infected individuals. HTLV-I infection is increasingly associated with clinical manifestations. To determine the prevalence of clinical manifestations in HTLV-I infected individuals, we conducted a cross-sectional study of 115 HTLV-I-infected blood donors without myelopathy and 115 age- and sex-matched seronegative controls. Subjects answered a standardized questionnaire and underwent physical examination. Compared with controls, HTLV-I-infected subjects were more likely to report arm or leg weakness (OR = 3.8, 95% CI: 1.4-10.2; OR = 4.0, 95% CI: 1.6-9.8, respectively), hand or foot numbness (OR = 2.1, 95% CI: 1.1-3.9; OR = 4.8, 95% CI: 2.0-11.7, respectively), arthralgia (OR = 3.3, 95% CI: 1.7-6.4), nocturia (OR = 2.7, 95% CI: 1.04-6.8), erectile dysfunction (OR = 4.0, 95% CI: 1.6-9.8), and to have gingivitis (OR = 3.8, 95% CI: 1.8-7.9), periodontitis (OR = 10.0, 95% CI: 2.3-42.8), and dry oral mucosa (OR = 7.5, 95% CI: 1.7-32.8). HTLV-I infection is associated with a variety of clinical manifestations, which may occur in patients who have not developed myelopathy.  (+info)

Sleep and aging: 2. Management of sleep disorders in older people. (6/56)

The treatment of sleep-related illness in older patients must be undertaken with an appreciation of the physiologic changes associated with aging. Insomnia is common among older people. When it occurs secondary to another medical condition, treatment of the underlying disorder is imperative. Benzodiazepines, although potentially effective, must be used with care and in conservative doses. Daytime sedation, a common side effect, may limit use of benzodiazepines. Newer non-benzodiazepine drugs appear to be promising. Rapid eye movement (REM) sleep behaviour disorder can be treated with clonazepam, levodopa-carbidopa or newer dopaminergic agents such as pramipexole. Sleep hygiene is important to patients with narcolepsy. Excessive daytime sleepiness can be treated with central stimulants; cataplexy may be improved with an antidepressant. Restless legs syndrome and periodic leg-movement disorder are treated with benzodiazepines or dopaminergic agents such as levodopa-carbidopa and, more recently, newer dopamine agonists. Treatment of obstructive sleep apnea includes weight reduction and proper sleep positioning (on one's side), but may frequently necessitate the use of a continuous positive air-pressure (CPAP) device. When used regularly, CPAP machines are very effective in reducing daytime fatigue and the sequelae of untreated obstructive sleep apnea.  (+info)

Effects of walking exercise on nocturia in the elderly. (7/56)

We investigated whether nocturia in the elderly was improved by walking exercise, which involved walking rapidly for 30 min or more in the evening or night for 8 weeks. A questionnaire related to micturition and exercise, blood pressure, body composition analysis, blood biochemistry tests, and urinalysis were performed before and after 8 weeks of exercise to investigate the effects of walking. Thirty men (71 years old on average) continued the walking exercise for long enough to undergo evaluation. The number of episodes of nocturia decreased significantly (p < 0.001) from 3.3 +/- 0.7 to 1.9 +/- 0.8 after 8 weeks of walking exercise. The daytime urinary frequency, blood pressure, body weight, body fat ratio, edema ratio, serum catecholamines, triglycerides, and total cholesterol were also decreased. After 8 weeks of exercise, 20 of the subjects (67%) stated that sleep was deeper than before exercise. Assessment of the overall improvement showed that excellent or good results were obtained in 18 patients (60%). The main factor related to the influence of walking exercise on nocturia was that sleep became deeper, which increased the arousal threshold bladder volume. Walking exercise may also have a preventive effect on lifestyle-related diseases.  (+info)

Enuresis is a common and persistent problem among children and young adults with sickle cell anemia. (8/56)

 (+info)

Nocturia is a common symptom characterized by the need to wake up during the night one or more times to urinate. While it's normal to urinate a few times during the night, nocturia is defined as having to urinate more than twice per night, which can disrupt sleep and lead to daytime fatigue and sleepiness.

Nocturia can be caused by various factors, including underlying medical conditions such as diabetes, bladder infections, enlarged prostate, or sleep disorders like sleep apnea. It can also be a side effect of certain medications. In some cases, nocturia may be a symptom of more serious conditions, so it's important to speak with a healthcare provider if you experience frequent nighttime urination.

Urination disorders, also known as lower urinary tract symptoms (LUTS), refer to a range of clinical conditions that affect the bladder and urethra, resulting in abnormalities in the storage, transportation, and evacuation of urine. These disorders can be categorized into voiding symptoms, such as hesitancy, straining, slow stream, intermittency, and terminal dribble; and storage symptoms, including frequency, urgency, nocturia, and urge incontinence.

The causes of urination disorders are diverse, encompassing congenital abnormalities, neurological conditions, infections, inflammation, medications, and age-related changes. Common underlying pathologies include bladder overactivity, detrusor muscle instability, underactive bladder, and obstruction of the urethra.

Urination disorders can significantly impact an individual's quality of life, causing physical discomfort, sleep disturbances, emotional distress, and social isolation. Accurate diagnosis and appropriate management require a comprehensive assessment of the patient's medical history, physical examination, urinalysis, and urodynamic studies. Treatment options may include behavioral modifications, pelvic floor exercises, bladder training, medications, neuromodulation, and surgical interventions.

Antidiuretic agents are medications or substances that reduce the amount of urine produced by the body. They do this by increasing the reabsorption of water in the kidneys, which leads to a decrease in the excretion of water and solutes in the urine. This can help to prevent dehydration and maintain fluid balance in the body.

The most commonly used antidiuretic agent is desmopressin, which works by mimicking the action of a natural hormone called vasopressin (also known as antidiuretic hormone or ADH). Vasopressin is produced by the pituitary gland and helps to regulate water balance in the body. When the body's fluid levels are low, vasopressin is released into the bloodstream, where it causes the kidneys to reabsorb more water and produce less urine.

Antidiuretic agents may be used to treat a variety of medical conditions, including diabetes insipidus (a rare disorder that causes excessive thirst and urination), bedwetting in children, and certain types of headaches. They may also be used to manage fluid balance in patients with kidney disease or heart failure.

It is important to use antidiuretic agents only under the supervision of a healthcare provider, as they can have side effects and may interact with other medications. Overuse or misuse of these drugs can lead to water retention, hyponatremia (low sodium levels in the blood), and other serious complications.

Polyuria is a medical term that describes the production of large volumes of urine, typically defined as exceeding 2.5-3 liters per day in adults. This condition can lead to frequent urination, sometimes as often as every one to two hours, and often worsens during the night (nocturia). Polyuria is often a symptom of an underlying medical disorder such as diabetes mellitus or diabetes insipidus, rather than a disease itself. Other potential causes include kidney diseases, heart failure, liver cirrhosis, and certain medications. Proper diagnosis and treatment of the underlying condition are essential to manage polyuria effectively.

Overactive bladder (OAB) is a urological condition characterized by the involuntary contraction of the detrusor muscle of the urinary bladder, leading to symptoms such as urgency, frequency, and nocturia (the need to wake up at night to urinate), with or without urge incontinence (the involuntary loss of urine associated with a strong desire to void). It is important to note that OAB is not necessarily related to bladder volume or age-related changes, and it can significantly impact an individual's quality of life. The exact cause of OAB is not fully understood, but it may be associated with neurological disorders, certain medications, infections, or other underlying medical conditions. Treatment options for OAB include behavioral modifications, pelvic floor exercises, bladder training, medications, and, in some cases, surgical interventions.

Lower urinary tract symptoms (LUTS) refer to a group of clinical symptoms related to the lower urinary tract, including the bladder and urethra. These symptoms can be categorized into storage, voiding, and post-micturition symptoms. Storage symptoms include frequency, urgency, nocturia, and urinary incontinence. Voiding symptoms consist of hesitancy, slow stream, straining, and intermittent flow. Post-micturition symptoms include a feeling of incomplete bladder emptying and post-void dribbling. LUTS can be caused by various underlying conditions such as benign prostatic hyperplasia (BPH), overactive bladder (OAB), urinary tract infection, neurogenic bladder dysfunction, or bladder cancer. The evaluation and management of LUTS require a comprehensive assessment of the patient's medical history, physical examination, and appropriate diagnostic tests to determine the underlying cause and develop an effective treatment plan.

Nocturnal enuresis, also known as bedwetting, is a medical condition where an individual, usually a child, urinates involuntarily during sleep. It is considered to be a disorder when it occurs in children over the age of 5 years old, and is more common in boys than girls. Nocturnal enuresis can have various causes, including delayed development of bladder control, small bladder capacity, sleep disorders, urinary tract infections, structural or neurological abnormalities, and family history. Treatment options may include behavioral interventions, such as bladder training and fluid restriction, medications, or a combination of both.

Phenylpropanolamine is a decongestant and appetite suppressant that has been used in over-the-counter and prescription medications. It works by narrowing blood vessels in the nose, which can help to relieve nasal congestion. As an appetite suppressant, it is thought to work by affecting certain chemicals in the brain that control appetite.

However, phenylpropanolamine has been associated with an increased risk of hemorrhagic stroke (bleeding in the brain) and other cardiovascular events, particularly in women who are otherwise healthy but have a history of high blood pressure or smoking. As a result, the U.S. Food and Drug Administration (FDA) advised manufacturers to stop selling over-the-counter products containing phenylpropanolamine in 2005.

It is important to note that this substance should only be used under the supervision of a healthcare professional, and individuals should always follow their doctor's instructions carefully when taking any medication.

Desmopressin, also known as 1-deamino-8-D-arginine vasopressin (dDAVP), is a synthetic analogue of the natural hormone arginine vasopressin. It is commonly used in medical practice for the treatment of diabetes insipidus, a condition characterized by excessive thirst and urination due to lack of antidiuretic hormone (ADH).

Desmopressin works by binding to V2 receptors in the kidney, which leads to increased water reabsorption and reduced urine production. It also has some effect on V1 receptors, leading to vasoconstriction and increased blood pressure. However, its primary use is for its antidiuretic effects.

In addition to its use in diabetes insipidus, desmopressin may also be used to treat bleeding disorders such as hemophilia and von Willebrand disease, as it can help to promote platelet aggregation and reduce bleeding times. It is available in various forms, including nasal sprays, injectable solutions, and oral tablets or dissolvable films.

'Angelica archangelica' is the botanical name for a plant species also known as Garden Angelica or Wild Celery. It belongs to the family Apiaceae and is native to temperate regions of Europe, northern Asia, and Greenland. The plant can grow up to 2 meters tall and has large, bright green, compound leaves and umbels of small white flowers.

The root, seeds, and stems of 'Angelica archangelica' have been used in traditional medicine and cooking for centuries. In herbal medicine, the root is often used to treat digestive problems such as gas, bloating, and loss of appetite, while the seeds are used to alleviate menstrual cramps and respiratory issues. The plant contains several bioactive compounds, including essential oils, coumarins, and furanocoumarins, which contribute to its medicinal properties.

However, it is important to note that 'Angelica archangelica' can interact with certain medications and may cause adverse effects in some individuals. Therefore, it is recommended to consult a healthcare professional before using this plant for medicinal purposes.

Prostatic hyperplasia, also known as benign prostatic hyperplasia (BPH), is a noncancerous enlargement of the prostate gland. The prostate gland surrounds the urethra, the tube that carries urine and semen out of the body. When the prostate gland enlarges, it can squeeze or partially block the urethra, causing problems with urination, such as a weak stream, difficulty starting or stopping the flow, and more frequent urination, especially at night. Prostatic hyperplasia is a common condition as men age and does not necessarily lead to cancer. However, it can cause significant discomfort and decreased quality of life if left untreated. Treatment options include medications, minimally invasive procedures, and surgery.

Urodynamics is a medical test that measures the function and performance of the lower urinary tract, which includes the bladder, urethra, and sphincters. It involves the use of specialized equipment to record measurements such as bladder pressure, urine flow rate, and residual urine volume. The test can help diagnose various urinary problems, including incontinence, urinary retention, and overactive bladder.

During the test, a small catheter is inserted into the bladder through the urethra to measure bladder pressure while filling it with sterile water or saline solution. Another catheter may be placed in the rectum to record abdominal pressure. The patient is then asked to urinate, and the flow rate and any leaks are recorded.

Urodynamics can help identify the underlying cause of urinary symptoms and guide treatment decisions. It is often recommended for patients with complex or persistent urinary problems that have not responded to initial treatments.

I apologize, but "Alabama" is not a medical term or condition. It is the name of one of the states in the United States of America, located in the southeastern region. The term "Alabaman" is used to describe someone from this state. If you have any questions related to medical terminology or health concerns, I would be happy to help answer those for you.

Phenylpropionates are a group of organic compounds that contain a phenyl group and a propionate group. In the context of pharmaceuticals, phenylpropionates often refer to a specific type of esterified hormone, such as testosterone phenylpropionate or nandrolone phenylpropionate. These esters are used in some forms of anabolic-androgenic steroids and are created by attaching a phenylpropionate group to the parent hormone molecule. This modification allows for a slower release and longer duration of action when administered intramuscularly.

It is important to note that these substances have medical uses, but they also carry risks and potential side effects, especially when used inappropriately or without medical supervision. They are controlled substances in many countries due to their potential for misuse and abuse.

Cresols are a group of chemical compounds that are phenolic derivatives of benzene, consisting of methyl substituted cresidines. They have the formula C6H4(OH)(\_3CH3). There are three isomers of cresol, depending on the position of the methyl group: ortho-cresol (m-cresol), meta-cresol (p-cresol), and para-cresol (o-cresol). Cresols are used as disinfectants, antiseptics, and preservatives in various industrial and commercial applications. They have a characteristic odor and are soluble in alcohol and ether. In medical terms, cresols may be used as topical antiseptic agents, but they can also cause skin irritation and sensitization.

No FAQ available that match "nocturia"

No images available that match "nocturia"